Literature DB >> 9046252

Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma.

A G Konstas1, D A Mantziris, W C Stewart.   

Abstract

OBJECTIVE: To describe and compare the diurnal intraocular pressure (IOP) variation in patients with exfoliation glaucoma (EXG) and primary open-angle glaucoma (POAG). PATIENTS AND
DESIGN: We prospectively investigated consecutive Greek patients with newly diagnosed untreated EXG and POAG. All patients were admitted to our ophthalmology department for 24-hour IOP measurements according to a standard protocol. After matching for age, we compared 40 pairs of patients with these 2 glaucomas.
RESULTS: Patients with EXG showed a significantly higher mean range of IOP (13.5 vs 8.5 mm Hg for POAG; unpaired t test, P < .001), higher maximum IOP (mean, 38.2 vs 26.9 mm Hg for POAG; unpaired t test, P < .001), and higher minimum IOP (mean, 24.7 vs 18.4 mm Hg for POAG; unpaired t test, P < .001) Patients with EXG more often demonstrated an IOP range higher than 15 mm Hg (35% vs only 7.5% for POAG). Importantly, in 45% of patients with EXG and 22.5% of patients with POAG, the peak level of IOP was found outside office hours. There was no significant difference in visual function (visual acuity, cupping, visual field) at diagnosis between the 2 glaucoma groups.
CONCLUSION: Significant fluctuation in the diurnal curve of the IOP distinguishes EXG from POAG and may be an important factor in predicting any subsequent poor response to medical therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9046252     DOI: 10.1001/archopht.1997.01100150184006

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  32 in total

1.  Diurnal variation of intraocular pressure and its correlation with retinal nerve fiber analysis in Turkish patients with exfoliation syndrome.

Authors:  Koray Gumus; Banu Bozkurt; Baris Sonmez; Murat Irkec; Mehmet Orhan; Osman Saracbasi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-02       Impact factor: 3.117

Review 2.  The medical and surgical management of pseudoexfoliation glaucoma.

Authors:  Manishi A Desai; Richard K Lee
Journal:  Int Ophthalmol Clin       Date:  2008

3.  The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP.

Authors:  Suzan Guven Yilmaz; Cumali Degirmenci; Yunus Emre Karakoyun; Emil Yusifov; Halil Ates
Journal:  Int Ophthalmol       Date:  2017-06-14       Impact factor: 2.031

Review 4.  [Diagnosis and therapy of pseudoexfoliation glaucoma].

Authors:  A G M Jünemann
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

5.  The Water-Drinking Test Revisited: An Analysis of Test Results in Subjects with Glaucoma.

Authors:  M Reza Razeghinejad; Zahra Tajbakhsh; M Hossein Nowroozzadeh; Shane J Havens; Deepta Ghate; Vikas Gulati
Journal:  Semin Ophthalmol       Date:  2017-05-24       Impact factor: 1.975

Review 6.  Glaucoma: genes, phenotypes, and new directions for therapy.

Authors:  Bao Jian Fan; Janey L Wiggs
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

7.  Trabeculotomy combined with phacoemulsification, intraocular lens implantation and sinusotomy for exfoliation glaucoma.

Authors:  Takeo Fukuchi; Jun Ueda; Tomoko Nakatsue; Kieko Suda; Hiroaki Hara; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2011-05-11       Impact factor: 2.447

8.  [Continuous intraocular pressure measurement: First results with a pressure-sensitive contact lens].

Authors:  A Hediger; C Kniestedt; S Zweifel; P Knecht; J Funk; H Kanngiesser
Journal:  Ophthalmologe       Date:  2009-12       Impact factor: 1.059

9.  Ocular perfusion pressure and retrobulbar haemodynamics in pseudoexfoliative glaucoma.

Authors:  Fernando Galassi; Barbara Giambene; Ugo Menchini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-31       Impact factor: 3.117

10.  Peripapillary atrophy in the unilateral exfoliation syndrome.

Authors:  Päivi Puska; Mika Harju; Ron Liebkind
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-01-28       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.